A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: 2-Aminopurine; Famciclovir

Criteria

Inclusion Criteria:

• Males or non-pregnant females at least 18 years of age with HSV-2 seropositive serology with or without history of clinically diagnosed recurrent genital herpes

Exclusion Criteria:

• Pregnancy

• History of renal dysfunction

• Use of immunosuppressive therapy, including steroids (other than topical or inhaled), or use of probenecid

• Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure